Shareholders Foundation Announces Lawsuit for Pacira BioSciences, Inc. Investors Amid Patent Controversies

In recent developments for investors of Pacira BioSciences, Inc. (NASDAQ: PCRX), a lawsuit has been initiated by the Shareholders Foundation, Inc. This legal action comes as alarming questions about the company's patent protections on its key product, Exparel, have surfaced. According to the complaint filed on January 13, 2025, the plaintiff accuses the defendants of issuing misleading statements and failing to disclose critical information. This includes the company's knowledge that its primary patent, the '495 patent, was not as robust as publicly claimed. The legal troubles began when the United States District Court for the District of New Jersey ruled in favor of eVenus Pharmaceutical Laboratories, leading to heightened concern from investors. Pacira asserted that Exparel, which represents a significant portion—approximately 80%—of its revenue, was under sufficient patent protection to support marketing and expansion efforts. However, the court's ruling suggested otherwise, indicating potential vulnerability to generic competition. Customers who invested in Pacira BioSciences prior to August 2023 and still hold shares are encouraged to reach out to the Shareholders Foundation to explore their options. This situation raises important questions regarding investor transparency and corporate governance within the pharmaceutical industry. The outcome of this lawsuit could have significant implications not only for Pacira’s future but also for shareholder rights in the sector. As the case unfolds, stakeholders will be closely monitoring its trajectory and potential impact. The Shareholders Foundation acts as a legal monitoring service, informing investors about class actions and related legal matters in the financial market. While it doesn’t provide legal counsel, it offers crucial resources for those affected by the potential outcomes of this case. With such high stakes involved, this situation underscores the necessity for vigilant oversight and transparent communication from corporations to their investors.